UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Extended RAS Gene Mutation Testing in Metastatic Colorectal Carcinoma to Predict Response to Anti-Epidermal Growth Factor Receptor Monoclonal Antibody Therapy: American Society of Clinical Oncology Provisional Clinical Opinion Update 2015

Journal of clinical oncology, 2016-01, Vol.34 (2), p.179-185

2016

Volltextzugriff (PDF)

Oxaliplatin As Adjuvant Therapy for Colon Cancer: Updated Results of NSABP C-07 Trial, Including Survival and Subset Analyses

Journal of clinical oncology, 2011-10, Vol.29 (28), p.3768-3774

2011

Volltextzugriff (PDF)

Capecitabine and Oxaliplatin in the Preoperative Multimodality Treatment of Rectal Cancer: Surgical End Points From National Surgical Adjuvant Breast and Bowel Project Trial R-04

Journal of clinical oncology, 2014-06, Vol.32 (18), p.1927-1934

2014

Volltextzugriff (PDF)

Preoperative Multimodality Therapy Improves Disease-Free Survival in Patients With Carcinoma of the Rectum: NSABP R-03

Journal of clinical oncology, 2009-11, Vol.27 (31), p.5124-5130

2009

Volltextzugriff (PDF)

American Society of Clinical Oncology Provisional Clinical Opinion: Testing for KRAS Gene Mutations in Patients With Metastatic Colorectal Carcinoma to Predict Response to Anti–Epidermal Growth Factor Receptor Monoclonal Antibody Therapy

Journal of clinical oncology, 2009-04, Vol.27 (12), p.2091-2096

2009

Volltextzugriff (PDF)

Rectal cancer patients younger than 50 years lack a survival benefit from NCCN guideline–directed treatment for stage II and III disease

Cancer, 2018-09, Vol.124 (17), p.3510-3519

2018

Volltextzugriff (PDF)

Phase III Trial Assessing Bevacizumab in Stages II and III Carcinoma of the Colon: Results of NSABP Protocol C-08

Journal of clinical oncology, 2011-01, Vol.29 (1), p.11-16

2011

Volltextzugriff (PDF)

Bevacizumab in Stage II-III Colon Cancer: 5-Year Update of the National Surgical Adjuvant Breast and Bowel Project C-08 Trial

Journal of clinical oncology, 2013-01, Vol.31 (3), p.359-364

2013

Volltextzugriff (PDF)

Initial Safety Report of NSABP C-08: A Randomized Phase III Study of Modified FOLFOX6 With or Without Bevacizumab for the Adjuvant Treatment of Patients With Stage II or III Colon Cancer

Journal of clinical oncology, 2009-07, Vol.27 (20), p.3385-3390

2009

Volltextzugriff (PDF)

Prognostic and Predictive Roles of High-Degree Microsatellite Instability in Colon Cancer: A National Cancer Institute–National Surgical Adjuvant Breast and Bowel Project Collaborative Study

Journal of clinical oncology, 2007-03, Vol.25 (7), p.767-772

2007

Volltextzugriff (PDF)

ACCENT-Based Web Calculators to Predict Recurrence and Overall Survival in Stage III Colon Cancer

JNCI : Journal of the National Cancer Institute, 2014-12, Vol.106 (12), p.1

2014

Volltextzugriff (PDF)

NSABP FB-10: a phase Ib/II trial evaluating ado-trastuzumab emtansine (T-DM1) with neratinib in women with metastatic HER2-positive breast cancer

Breast cancer research : BCR, 2024-04, Vol.26 (1), p.69-69, Article 69

2024

Volltextzugriff (PDF)

Correction: NSABP FB-10: a phase Ib/II trial evaluating ado-trastuzumab emtansine (T-DM1) with neratinib in women with metastatic HER2-positive breast cancer

Breast cancer research : BCR, 2024-05, Vol.26 (1), p.83-83, Article 83

2024

Volltextzugriff (PDF)

NSABP FB-7: a phase II randomized neoadjuvant trial with paclitaxel + trastuzumab and/or neratinib followed by chemotherapy and postoperative trastuzumab in HER2 + breast cancer

Breast cancer research : BCR, 2019-12, Vol.21 (1), p.133-133, Article 133

2019

Volltextzugriff (PDF)

Molecular subtypes of colorectal cancer in pre-clinical models show differential response to targeted therapies: Treatment implications beyond KRAS mutations

PloS one, 2018-08, Vol.13 (8), p.e0200836-e0200836

2018

Volltextzugriff (PDF)

Alternative End Points to Evaluate a Therapeutic Strategy in Advanced Colorectal Cancer: Evaluation of Progression-Free Survival, Duration of Disease Control, and Time to Failure of Strategy—An Aide et Recherche en Cancérologie Digestive Group Study

Journal of clinical oncology, 2011-11, Vol.29 (31), p.4199-4204

2011

Volltextzugriff (PDF)

BCL-XL PROTAC degrader DT2216 synergizes with sotorasib in preclinical models of KRASG12C-mutated cancers

Journal of hematology and oncology, 2022-03, Vol.15 (1), p.23-23, Article 23

2022

Volltextzugriff (PDF)

Phase III Evaluation of Treatment Combinations in Three-Arm Trials

Journal of clinical oncology, 2024-10

2024

Volltextzugriff (PDF)

Association of Obesity With DNA Mismatch Repair Status and Clinical Outcome in Patients With Stage II or III Colon Carcinoma Participating in NCCTG and NSABP Adjuvant Chemotherapy Trials

Journal of clinical oncology, 2012-02, Vol.30 (4), p.406-412

2012

Volltextzugriff (PDF)

Correction to: NSABP FB-7: a phase II randomized neoadjuvant trial with paclitaxel + trastuzumab and/or neratinib followed by chemotherapy and postoperative trastuzumab in HER2+ breast cancer

Breast cancer research : BCR, 2020-01, Vol.22 (1), p.9-9, Article 9

2020

Volltextzugriff (PDF)

The Master Protocol Concept

Seminars in oncology, 2015-10, Vol.42 (5), p.724-730

2015

Volltextzugriff (PDF)

Prognostic Value of Thymidylate Synthase, Ki-67, and p53 in Patients With Dukes’ B and C Colon Cancer: A National Cancer Institute–National Surgical Adjuvant Breast and Bowel Project Collaborative Study

Journal of clinical oncology, 2003-01, Vol.21 (2), p.241-250

2003

Volltextzugriff (PDF)

Clinical Benefit Scales and Trial Design: Some Statistical Issues

JNCI : Journal of the National Cancer Institute, 2022-09, Vol.114 (9), p.1222-1227

2022

Volltextzugriff (PDF)

Neoadjuvant 5-FU or Capecitabine Plus Radiation With or Without Oxaliplatin in Rectal Cancer Patients: A Phase III Randomized Clinical Trial

JNCI : Journal of the National Cancer Institute, 2015-11, Vol.107 (11), p.djv248

2015

Volltextzugriff (PDF)

1 – 25 von 313

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(300)
Mit Volltextzugriff
(268)

Publikationsform

Sprache

Englisch
(313)
Japanisch
(1)

Erscheinungsjahr

n.n

Thema

Science & Technology
(174)
Life Sciences & Biomedicine
(170)
Humans
(166)
Oncology
(121)
Biological And Medical Sciences
(95)
Medical Sciences
(85)
Pharmacology. Drug Treatments
(60)
Female
(59)
Antineoplastic Agents
(52)
Male
(51)
Middle Aged
(47)
Adult
(38)
Aged
(35)
Tumors
(35)
Antineoplastic Combined Chemotherapy Protocols - Therapeutic Use
(33)
Chemotherapy
(32)
Fluorouracil - Administration & Dosage
(29)
Pharmacology & Pharmacy
(28)
Prognosis
(27)
Tumor Cells, Cultured
(27)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Extended RAS Gene Mutation Testing in Metastatic Colorectal Carcinoma to Predict Response to Anti-Epidermal Growth Factor Receptor Monoclonal Antibody Therapy: American Society of Clinical Oncology Provisional Clinical Opinion Update 2015

Oxaliplatin As Adjuvant Therapy for Colon Cancer: Updated Results of NSABP C-07 Trial, Including Survival and Subset Analyses

Molecular Biomarkers for the Evaluation of Colorectal Cancer: Guideline From the American Society for Clinical Pathology, College of American Pathologists, Association for Molecular Pathology, and the American Society of Clinical Oncology

Capecitabine and Oxaliplatin in the Preoperative Multimodality Treatment of Rectal Cancer: Surgical End Points From National Surgical Adjuvant Breast and Bowel Project Trial R-04

Preoperative Multimodality Therapy Improves Disease-Free Survival in Patients With Carcinoma of the Rectum: NSABP R-03

American Society of Clinical Oncology Provisional Clinical Opinion: Testing for KRAS Gene Mutations in Patients With Metastatic Colorectal Carcinoma to Predict Response to Anti–Epidermal Growth Factor Receptor Monoclonal Antibody Therapy

Rectal cancer patients younger than 50 years lack a survival benefit from NCCN guideline–directed treatment for stage II and III disease

Phase III Trial Assessing Bevacizumab in Stages II and III Carcinoma of the Colon: Results of NSABP Protocol C-08

Bevacizumab in Stage II-III Colon Cancer: 5-Year Update of the National Surgical Adjuvant Breast and Bowel Project C-08 Trial

Initial Safety Report of NSABP C-08: A Randomized Phase III Study of Modified FOLFOX6 With or Without Bevacizumab for the Adjuvant Treatment of Patients With Stage II or III Colon Cancer

Prognostic and Predictive Roles of High-Degree Microsatellite Instability in Colon Cancer: A National Cancer Institute–National Surgical Adjuvant Breast and Bowel Project Collaborative Study

ACCENT-Based Web Calculators to Predict Recurrence and Overall Survival in Stage III Colon Cancer

NSABP FB-10: a phase Ib/II trial evaluating ado-trastuzumab emtansine (T-DM1) with neratinib in women with metastatic HER2-positive breast cancer

Correction: NSABP FB-10: a phase Ib/II trial evaluating ado-trastuzumab emtansine (T-DM1) with neratinib in women with metastatic HER2-positive breast cancer

NSABP FB-7: a phase II randomized neoadjuvant trial with paclitaxel + trastuzumab and/or neratinib followed by chemotherapy and postoperative trastuzumab in HER2 + breast cancer

Molecular subtypes of colorectal cancer in pre-clinical models show differential response to targeted therapies: Treatment implications beyond KRAS mutations

Alternative End Points to Evaluate a Therapeutic Strategy in Advanced Colorectal Cancer: Evaluation of Progression-Free Survival, Duration of Disease Control, and Time to Failure of Strategy—An Aide et Recherche en Cancérologie Digestive Group Study

BCL-XL PROTAC degrader DT2216 synergizes with sotorasib in preclinical models of KRASG12C-mutated cancers

Phase III Evaluation of Treatment Combinations in Three-Arm Trials

Association of Obesity With DNA Mismatch Repair Status and Clinical Outcome in Patients With Stage II or III Colon Carcinoma Participating in NCCTG and NSABP Adjuvant Chemotherapy Trials

Correction to: NSABP FB-7: a phase II randomized neoadjuvant trial with paclitaxel + trastuzumab and/or neratinib followed by chemotherapy and postoperative trastuzumab in HER2+ breast cancer

The Master Protocol Concept

Prognostic Value of Thymidylate Synthase, Ki-67, and p53 in Patients With Dukes’ B and C Colon Cancer: A National Cancer Institute–National Surgical Adjuvant Breast and Bowel Project Collaborative Study

Clinical Benefit Scales and Trial Design: Some Statistical Issues

Neoadjuvant 5-FU or Capecitabine Plus Radiation With or Without Oxaliplatin in Rectal Cancer Patients: A Phase III Randomized Clinical Trial

Suchergebnisse filtern